Calliditas Therapeutics raise US$90m in Nasdaq IPO
Swedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1243 entries already.
Entries by Thomas Gabrielczyk
Hyloris Pharmaceuticals prepared to go public
/in News/by Thomas GabrielczykBelgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.
NodThera bags US$55m in Series B round
/in News/by Thomas GabrielczykNodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.
Bacterial colonisation differs by tumour type
/in News/by Thomas GabrielczykAn analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.
Novo Holdings invests into AI CRO ExScientia
/in News/by Thomas GabrielczykNovo Holdings leads the current US$60m Series C round of ExScientia Ltd, the world-leading artificial intelligence (AI)-driven drug discovery company.
Poxel SA raises 17.7m through capital increase
/in News/by Thomas GabrielczykMetabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at 0.02 per share reserved to specified investors.
British scientists start Phase II on COVID-19 vaccine
/in News/by Thomas GabrielczykResearchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.
New algorithm predicts rheumatoid arthritis
/in News/by Thomas GabrielczykBased on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases.
SARS-CoV2 antibody tests: not suited for individual diagnosis?
/in News/by Thomas GabrielczykAn international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Vaccine to protect from any viral infection
/in News/by Thomas GabrielczykTwo companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.